MedTrace Logo

Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19

NCT04632706 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-12-27

Study results available
· View outcomes & findings →

Summary

An early stage trial to check how safe and tolerable, as well as how the body handles continuous daily use of Active IMP over 28 days in healthy volunteers.

Conditions

  • Covid19

Interventions

DRUG

Ivermectin

Ivermectin: Investigation of the safety, tolerability and the pharmacokinetic profile of the active IMP in an exploratory study

DRUG

Placebo

Matching Placebo to the Active IMP.

Sponsors & Collaborators

  • MedinCell S.A

    lead INDUSTRY

Principal Investigators

  • Pui Man Leung, MD · MAC Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-22
Primary Completion
2021-03-09
Completion
2021-03-09

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04632706 on ClinicalTrials.gov